Viking Therapeutics
VKTX
370 hedge funds and large institutions have $1.87B invested in Viking Therapeutics in 2025 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 142 increasing their positions, 108 reducing their positions, and 69 closing their positions.
112% more call options, than puts
Call options by funds: $242M | Put options by funds: $114M
31% more repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 108
4.45% less ownership
Funds ownership: 67.83% → 63.38% (-4.4%)
5% less funds holding
Funds holding: 391 → 370 (-21)
7% less capital invested
Capital invested by funds: $2.02B → $1.87B (-$146M)
26% less first-time investments, than exits
New positions opened: 51 | Existing positions closed: 69
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$30.6M |
| 2 |
Two Sigma Investments
New York
|
+$23M |
| 3 |
State Street
Boston,
Massachusetts
|
+$22M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$18.4M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$120M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$21.5M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$20.2M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$16.9M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$15.9M |
VKTX Hedge Fund Activity: Q3 2025 in Review
370 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2025, worth a combined $1.87B — down 7.2% from $2.02B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of VKTX and 51 opened new positions — a net loss of 18 holders — while 108 trimmed existing stakes and 142 added.
The largest buyer was Citadel Advisors, adding an estimated $30.6M. The largest seller was Fidelity Investments, cutting an estimated $120M.
- 370 institutional investors held Viking Therapeutics (VKTX) as of Q3 2025, down from 391 in Q2 2025.
- Funds reported $1.87B of Viking Therapeutics stock for Q3 2025, down 7.2% quarter-over-quarter.
- 51 funds opened new Viking Therapeutics positions in Q3 2025 and 69 closed out, a net change of -18 holders.
- The largest Viking Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $30.6M added.
- The largest Viking Therapeutics seller in Q3 2025 was Fidelity Investments, an estimated $120M sold.
Based on aggregated 13F filings for Q3 2025.